<DOC>
	<DOCNO>NCT00523250</DOCNO>
	<brief_summary>A double-masked , randomize , vehicle-controlled , dose-response study assess safety ocular hypotensive efficacy AR-102 subject elevate intraocular pressure . The Null hypothesis ocular hypotensive efficacy dose AR-102 Ophthalmic Solution different vehicle .</brief_summary>
	<brief_title>Ocular Hypotensive Efficacy AR-102</brief_title>
	<detailed_description>A double-masked , randomize , vehicle-controlled , dose-response study assess safety ocular hypotensive efficacy AR-102 subject elevate intraocular pressure .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<criteria>18 year age great ( male , female childbearing potential ) . Diagnosis open angle glaucoma ( OAG ) ocular hypertension ( OHT ) study eye ( ) . Corrected visual acuity ETDRS eye +1.0 logMAR unit well Known hypersensitivity component formulation topical anesthetic Previous glaucoma intraocular surgery laser procedure study eye ( ) Clinically significant systemic disease ( e.g. , uncontrolled diabetes , myasthenia gravis , hepatic , renal , cardiovascular endocrine disorder ) might interfere study . Participation study involve investigational drug within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>